Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients

NCT00739648 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00739648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
April 30, 2010
Enrollment
322 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease